Block printing captured Lili Arnold's attention because of its relatively simple components and technique—no giant presses ...
Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.
Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...
March 10 (Reuters) - Eli Lilly (LLY.N), opens new tab plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and Mexico in the second half of ...
Earlier this week, Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial Zepbound (tirzepatide) to patients in the virtual care companies ...
The Lady Tigers gymnast couldn’t compete on senior night, but that wasn’t stopping her from crushing one last home leotard selfie. LSU’s Livvy Dunne competes on the floor during NCAA ...
(Photo courtesy of Adam Seif) Michael Headrick of Indianapolis wanted to start on a new GLP-1 medication for weight loss, so he mentioned Eli Lilly and Co.’s Zepbound to his doctor, who agreed ...
Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.
Last week, Eli Lilly said it would cut the monthly price of its starter dose of Zepbound to $349. The U.S. drugmaker also is making larger doses available for $499 through its self-pay program.
A UK startup that wants to bring protein degraders to the neurodegeneration field has closed a $31 million seed round.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback